Annual Total Liabilities
$4.17 B
+$122.37 M+3.02%
December 31, 2024
Summary
- As of March 8, 2025, ALNY annual total liabilities is $4.17 billion, with the most recent change of +$122.37 million (+3.02%) on December 31, 2024.
- During the last 3 years, ALNY annual total liabilities has risen by +$1.12 billion (+36.59%).
- ALNY annual total liabilities is now at all-time high.
Performance
ALNY Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$4.17 B
+$210.00 K+0.01%
December 31, 2024
Summary
- As of March 8, 2025, ALNY quarterly total liabilities is $4.17 billion, with the most recent change of +$210.00 thousand (+0.01%) on December 31, 2024.
- Over the past year, ALNY quarterly total liabilities has increased by +$122.37 million (+3.02%).
- ALNY quarterly total liabilities is now at all-time high.
Performance
ALNY Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
ALNY Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +3.0% | +3.0% |
| 3 y3 years | +36.6% | +3.0% |
| 5 y5 years | +336.3% | +3.0% |
ALNY Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +36.6% | at high | +37.6% |
| 5 y | 5-year | at high | +336.3% | at high | +348.8% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% |
Alnylam Pharmaceuticals Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $4.17 B(+3.0%) | $4.17 B(+0.0%) |
| Sep 2024 | - | $4.17 B(+4.0%) |
| Jun 2024 | - | $4.01 B(-0.8%) |
| Mar 2024 | - | $4.04 B(-0.2%) |
| Dec 2023 | $4.05 B(+9.3%) | $4.05 B(+1.1%) |
| Sep 2023 | - | $4.00 B(+5.1%) |
| Jun 2023 | - | $3.81 B(+4.4%) |
| Mar 2023 | - | $3.65 B(-1.4%) |
| Dec 2022 | $3.70 B(+21.3%) | $3.70 B(+2.8%) |
| Sep 2022 | - | $3.60 B(+14.2%) |
| Jun 2022 | - | $3.15 B(+4.0%) |
| Mar 2022 | - | $3.03 B(-0.7%) |
| Dec 2021 | $3.06 B(+27.8%) | $3.06 B(+12.5%) |
| Sep 2021 | - | $2.72 B(+2.3%) |
| Jun 2021 | - | $2.66 B(+14.0%) |
| Mar 2021 | - | $2.33 B(-2.6%) |
| Dec 2020 | $2.39 B(+150.0%) | $2.39 B(+14.3%) |
| Sep 2020 | - | $2.09 B(+6.0%) |
| Jun 2020 | - | $1.97 B(+112.4%) |
| Mar 2020 | - | $929.89 M(-2.8%) |
| Dec 2019 | $956.44 M(+250.6%) | $956.44 M(+2.3%) |
| Sep 2019 | - | $934.53 M(-2.6%) |
| Jun 2019 | - | $959.22 M(+105.4%) |
| Mar 2019 | - | $467.01 M(+71.2%) |
| Dec 2018 | $272.84 M(+19.5%) | $272.84 M(+38.1%) |
| Sep 2018 | - | $197.53 M(+17.2%) |
| Jun 2018 | - | $168.59 M(+0.2%) |
| Mar 2018 | - | $168.33 M(-26.3%) |
| Dec 2017 | $228.30 M(-33.4%) | $228.30 M(-23.8%) |
| Sep 2017 | - | $299.45 M(-3.8%) |
| Jun 2017 | - | $311.32 M(+2.7%) |
| Mar 2017 | - | $303.02 M(-11.5%) |
| Dec 2016 | $342.59 M(+181.3%) | $342.59 M(+15.0%) |
| Sep 2016 | - | $297.94 M(+5.0%) |
| Jun 2016 | - | $283.68 M(+121.8%) |
| Mar 2016 | - | $127.90 M(+5.0%) |
| Dec 2015 | $121.80 M(-15.0%) | $121.80 M(+6.3%) |
| Sep 2015 | - | $114.54 M(-6.2%) |
| Jun 2015 | - | $122.17 M(-7.6%) |
| Mar 2015 | - | $132.28 M(-7.7%) |
| Dec 2014 | $143.33 M | $143.33 M(+75.0%) |
| Sep 2014 | - | $81.88 M(-9.4%) |
| Jun 2014 | - | $90.39 M(-27.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2014 | - | $125.32 M(-16.6%) |
| Dec 2013 | $150.18 M(-2.1%) | $150.18 M(+0.2%) |
| Sep 2013 | - | $149.92 M(-2.9%) |
| Jun 2013 | - | $154.38 M(-3.5%) |
| Mar 2013 | - | $160.02 M(+4.3%) |
| Dec 2012 | $153.47 M(-6.4%) | $153.47 M(+5.7%) |
| Sep 2012 | - | $145.19 M(+11.5%) |
| Jun 2012 | - | $130.19 M(-8.9%) |
| Mar 2012 | - | $142.92 M(-12.8%) |
| Dec 2011 | $163.92 M(-30.3%) | $163.92 M(-10.1%) |
| Sep 2011 | - | $182.35 M(-10.7%) |
| Jun 2011 | - | $204.28 M(-8.6%) |
| Mar 2011 | - | $223.49 M(-4.9%) |
| Dec 2010 | $235.03 M(-22.5%) | $235.03 M(-6.7%) |
| Sep 2010 | - | $251.96 M(-8.3%) |
| Jun 2010 | - | $274.70 M(-5.8%) |
| Mar 2010 | - | $291.58 M(-3.9%) |
| Dec 2009 | $303.42 M(-13.9%) | $303.42 M(-3.3%) |
| Sep 2009 | - | $313.65 M(-6.1%) |
| Jun 2009 | - | $334.17 M(-6.1%) |
| Mar 2009 | - | $355.79 M(+0.9%) |
| Dec 2008 | $352.55 M(+19.7%) | $352.55 M(-6.1%) |
| Sep 2008 | - | $375.62 M(-1.4%) |
| Jun 2008 | - | $380.88 M(+34.4%) |
| Mar 2008 | - | $283.44 M(-3.8%) |
| Dec 2007 | $294.62 M(+658.7%) | $294.62 M(-5.6%) |
| Sep 2007 | - | $312.16 M(+672.9%) |
| Jun 2007 | - | $40.39 M(+8.2%) |
| Mar 2007 | - | $37.31 M(-3.9%) |
| Dec 2006 | $38.83 M(+6.2%) | $38.83 M(-2.3%) |
| Sep 2006 | - | $39.75 M(+7.3%) |
| Jun 2006 | - | $37.04 M(+3.5%) |
| Mar 2006 | - | $35.77 M(-2.2%) |
| Dec 2005 | $36.57 M(+83.2%) | $36.57 M(+81.2%) |
| Sep 2005 | - | $20.18 M(-6.0%) |
| Jun 2005 | - | $21.47 M(+11.6%) |
| Mar 2005 | - | $19.24 M(-3.6%) |
| Dec 2004 | $19.96 M(-67.7%) | $19.96 M(+13.7%) |
| Sep 2004 | - | $17.56 M(-1.3%) |
| Jun 2004 | - | $17.80 M(-77.3%) |
| Mar 2004 | - | $78.42 M(+26.7%) |
| Dec 2003 | $61.89 M(+198.2%) | $61.89 M |
| Dec 2002 | $20.76 M | - |
FAQ
- What is Alnylam Pharmaceuticals annual total liabilities?
- What is the all time high annual total liabilities for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals annual total liabilities year-on-year change?
- What is Alnylam Pharmaceuticals quarterly total liabilities?
- What is the all time high quarterly total liabilities for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals quarterly total liabilities year-on-year change?
What is Alnylam Pharmaceuticals annual total liabilities?
The current annual total liabilities of ALNY is $4.17 B
What is the all time high annual total liabilities for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high annual total liabilities is $4.17 B
What is Alnylam Pharmaceuticals annual total liabilities year-on-year change?
Over the past year, ALNY annual total liabilities has changed by +$122.37 M (+3.02%)
What is Alnylam Pharmaceuticals quarterly total liabilities?
The current quarterly total liabilities of ALNY is $4.17 B
What is the all time high quarterly total liabilities for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high quarterly total liabilities is $4.17 B
What is Alnylam Pharmaceuticals quarterly total liabilities year-on-year change?
Over the past year, ALNY quarterly total liabilities has changed by +$122.37 M (+3.02%)